The start of the rolling evaluation of the HIPRA (also known as PHH-1V) vaccine against COVID-19 for booster dose purposes has been announced by the European Medicines Agency.
As noted, this vaccine, which is produced by the Spanish company HIPRA and is protein-based, is intended for administration as a booster dose for adults who have completed their vaccination regimen with another vaccine. [THE DECISION OF THE COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) IS BASED ON PRELIMINARY RESULTS FROM LABORATORY TESTS AND CLINICAL TRIALS IN ADULTS.
(CNA)
CNA - Giorgos Kakouris
Contents of this article including associated images are owned by CNA
Views & opinions expressed are those of the author and/or CNA
Source
